APEX-Agents · Investment Banking

World228_JK_04

0/4Fail

APEX-Agents task World228_JK_04 in AI Agents for FDA and Pharma Promotional Compliance. Compare dual-harness agent runs across models — rubric criteria, scores, and public traces.

AI Agents for FDA and Pharma Promotional ComplianceInvestment Banking World 228Dual harnessGrader: rubric

Task IDtask_86de7a1a9d884d2bb1037ac181701a04

WorldInvestment Banking World 228

Expected outputmessage_in_console

Published runs4 models · dual config

Task prompt

What the agent was asked to do

Calculate the 2030E discounted EV/Revenue multiples for West Pharmaceutical, Stevanato Group, Schott Pharma, and Aptar Group. Reference the valuation model on the "Trading Comps" tab. Note that the financial and valuation metrics reflect 2025E assumptions. For each company, assume that the long-term revenue growth rate starting in 2026E is equal to its FY23 - FY24 YOY net sales growth rate, and the discount rates are as follows: West Pharmaceutical -> Reference WST 2024 10K for revenue growth -> Discount Rate: 9.4% Stevanato Group -> Reference Stevanto 2024 20-F for revenue growth -> Discount Rate: 8.8% Schott Pharma -> Reference Schott 2024 annual report for revenue growth -> Discount Rate: 10.0% Aptar Group -> Reference ATR 2024 10K for revenue growth -> Discount Rate: 7.4% Round the final output to one decimal and express it as a multiple. Print out what you find for me in here.

Published trajectories

Agent runs on this task

Curated dual-harness runs (parsed + original sandbox). Best scored run per model.

Model	Harness	Score	Result	Links
GPT-5.5showcase	dual	0/4	Fail	Share page Public trace
Gemini 3.1 Pro	dual	0/4	Fail	Share page Public trace
GPT-5.4 mini	dual	0/4	Fail	Share page Public trace
GPT-5.4 nano	dual	0/4	Fail	Share page Public trace

Grading rubric

Criteria and grader verdict (showcase run)

States West Pharmaceutical FY2030E Discounted EV/Revenue multiple is 10.3x
Fail
Evidence: <TEXT_RESPONSE> table states “West Pharmaceutical | 14.8x.” Assessment: Criterion requires stating West Pharmaceutical FY2030E Discounted EV/Revenue multiple is 10.3x; the response states 14.8x, so fail.
States Stevanato Group FY2030E Discounted EV/Revenue multiple is 4.9x
Fail
Evidence: <TEXT_RESPONSE> table states “Stevanato Group | 6.8x.” Assessment: Criterion requires stating Stevanato Group FY2030E Discounted EV/Revenue multiple is 4.9x; the response states 6.8x, so fail.
States Schott Pharma FY2030E Discounted EV/Revenue multiple is 7.0x
Fail
Evidence: <TEXT_RESPONSE> table states “Schott Pharma | 10.2x.” Assessment: Criterion requires stating Schott Pharma FY2030E Discounted EV/Revenue multiple is 7.0x; the response states 10.2x, so fail.
States Aptar Group FY2030E Discounted EV/Revenue multiple is 2.9x
Fail
Evidence: <TEXT_RESPONSE> table states “Aptar Group | 3.8x.” Assessment: Criterion requires stating Aptar Group FY2030E Discounted EV/Revenue multiple is 2.9x; the response states 3.8x, so fail.